California-based Spirox Inc. announced today that it has finalized a $45 million Series C round of financing, which will be used to move forward with its minimally invasive system to be used by Ear, Nose and Throat (ENT) physicians and plastic surgeons to treat patients with nasal obstruction.
Nasal obstruction is a significant problem that effects more than three million Americans each year. Generally, surgical procedures are performed to treat deviated septums, reduce the size of turbinates or prevent nasal valve collapse. But surgery increases morbidity, which makes it a last resort type of procedure.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Spirox is looking to make treating these conditions with a minimally invasive approach possible with its device.
The financing round was led by global investment firm KKR as well as HealthQuest Capital, Aisling Capital, Aperture Venture Partners and Venrock.